JAKs Are Better? Oral Inhibitors Could Beat Injected Biologics In RA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Buzz over data from trials with Janus-associated kinase inhibitors at the American College of Rheumatology meeting is heating up the debate over whether the class will ultimately beat injected biologics in rheumatoid arthritis